<DOC>
	<DOC>NCT01390870</DOC>
	<brief_summary>Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged prostate (EP). Adherence with EP therapy will be evaluated. The researchers believe that the majority of participants will report that they are compliant with therapy. The data source is a cross-sectional patient survey administered at one time point.</brief_summary>
	<brief_title>Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Males Aged 50 years or older Residents of the United States Receiving a prescription for an enlarged prostate (EP) treatment within 12 months prior to survey initiation Patients with prostate cancer no health/prescription insurance patients receiving medication(s) for EP on a PRN basis</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, adherence</keyword>
</DOC>